In 11 EBC samples obtained from the remaining subgroup of 12 KRAS mutation positive NSCLC patients’ samples the same mutated sequence was observed as in the cancer tissue (Table 5). This evidence concerns the gene KRAS and non-small cell lung carcinoma.